Linda Wolbers, MD
Pain Medicine · Capitola, CANPI 1093753899
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 82 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $692 and has fallen 68.3% since, to $219 in 2025.
Across 82 payments — averaging $33.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Saluda Medical Americas, Inc.$472
- MML US, Inc.$232
- Stryker$192
- Medtronic$191
- Abbott$191
- Teva Pharmaceuticals USA, Inc.$162
- plus $1K from 21 others
Across 13 payments — averaging $5363.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Saluda Medical Americas, Inc.$70K
What the payments were for
- Food & beverage$2,724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Saluda Medical Americas, Inc. | 5 | $472 |
| MML US, Inc. | 1 | $232 |
| Stryker | 1 | $192 |
| Medtronic | 2 | $191 |
| Abbott | 2 | $191 |
| Teva Pharmaceuticals USA, Inc. | 7 | $162 |
| Collegium Pharmaceutical, Inc. | 8 | $145 |
| Sentynl Therapeutics, Inc. | 7 | $113 |
| Biodelivery Sciences International, Inc. | 6 | $101 |
| Biohaven Pharmaceuticals, Inc. | 5 | $95 |
| Stimwave Technologies Incorporated | 1 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $91 |
| SPR Therapeutics, Inc | 1 | $73 |
| Nevro Corp. | 1 | $66 |
| Vanda Pharmaceuticals Inc. | 3 | $64 |
| Neurocrine Biosciences, Inc. | 3 | $63 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 4 | $56 |
| Ironshore Pharmaceuticals Inc. | 3 | $55 |
| AbbVie(2 entities) | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Vertical Pharmaceuticals, LLC | 1 | $23 |
| Lundbeck LLC | 1 | $19 |
| Bausch Health US, LLC | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ReActiv8$232
- Evoke$211
- mild Device Kit$192
- PROCLAIM$114
How this compares
$2,724 in reported general payments places this provider in the 55th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levorphanol Tartrate | 61 | $173,004 |
| Xtampza ErOxycodone Myristate | 13 | $8,677 |
| OxycontinOxycodone Hcl | 13 | $5,715 |
| Buprenorphine | 19 | $4,179 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 155 | $4,039 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 67 | $2,838 |
| Oxycodone Hcl | 96 | $2,490 |
| Fentanyl | 13 | $1,974 |
| Gabapentin | 105 | $1,474 |
| Morphine Sulfate ErMorphine Sulfate | 26 | $815 |
| Duloxetine Hcl | 52 | $764 |
| Buprenorphine Hcl | 17 | $727 |
| Tizanidine Hcl | 76 | $702 |
| Methadone Hcl | 49 | $657 |
| Pregabalin | 36 | $603 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $145 | $8,67713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 pain medicine providers in California.
Other pain medicine in Capitola
- Jason PopeSanta Rosa$2.1M
- Ramana NaiduLarkspur$1.4M
- Foead GeulaStudio City$1.3M
- Krishnan ChakravarthyTemecula$1.3M
- Kasra AmirdelfanWalnut Creek$783K
- Eric GrigsbyNapa$499K
- Jacqueline WeisbeinNapa$494K
- Gerald SacksSanta Monica$389K
- Samir ShethRoseville$356K
- Einar OttestadStanford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.